Back

A Dual-Action Mechanism to Prevent OX40 Signaling: The Structural Basis for the Differentiated Antagonist STAR-0310

Biris, N.; Zhao, C.; Macoin, J.; Fuller, J. R.; Blauvelt, A.; Chovatiya, R.; Bunick, C. G.

2025-09-19 pharmacology and toxicology
10.1101/2025.09.16.676329 bioRxiv
Show abstract

Atopic dermatitis (AD) is a chronic inflammatory disease sustained by dysregulated T cell activity. The OX40/OX40L pathway drives effector and memory T cell proliferation, survival, and cytokine production, making it a key therapeutic target. STAR-0310, a novel anti-OX40 antibody, binds a noncanonical epitope that sterically blocks receptor trimerization without inducing agonism. Structural and functional studies demonstrated a dual mechanism: prevention of new OX40/OX40L interactions and efficient disruption of pre-formed complexes, outperforming comparator antibodies. The pure antagonism and complex disruption capacity of STAR-0310 support its clinical evaluation (NCT06782477) as a differentiated OX40-targeted therapy for AD. HighlightsO_LINovel binding mechanism: STAR-0310 engages OX40 distal to the OX40L site, sterically blocking receptor trimerization without inducing agonism. C_LIO_LIDual action: Prevents formation of new OX40/OX40L complexes and efficiently disrupts pre-formed complexes sustaining inflammation. C_LIO_LIDifferentiation from competitors: Achieves greater efficiency in complex disruption compared with rocatinlimab and IMG-007 with no partial agonist activity. C_LIO_LIClinical potential: Pure antagonist profile supports ongoing evaluation of STAR-0310 (NCT06782477) as a best-in-class OX40 therapy for atopic dermatitis. C_LI

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.